ArticleActa pharmaceutica Sinica. B2023
Improving cancer immunotherapy
Article in Acta pharmaceutica Sinica. B, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 53 citations in OpenAlex.
- The role of thrombospondin-1 in dermatological conditions.Frontiers in medicine · 2026Review
- FSCN1 regulates TGF-β signalling to promote esophageal squamous cell carcinoma metastasis via stabilizing THBS1 mRNA.Communications biology · 2025Article
- THBS1 identificated as an endometriosis biomarker through evidence from single-cell and bulk transcriptomic profiling.iScience · 2025Article
- Review
- Thrombospondin-1 induces CD8Journal of ovarian research · 2025Article
- Microglia-targeting nanosystems that cooperatively deliver Chinese herbal ingredients alleviate behavioral and cognitive deficits in Alzheimer's disease model mice.Journal of nanobiotechnology · 2025Article
- siRNA micelleplexes-mediated glutamine metabolism re-engineering for vascular normalization-boosted photo-immunotherapy.Acta pharmaceutica Sinica. B · 2025Article
- Interplay Between TGFβ1 Signaling and Cancer-Testis Antigen MAGEB2: A New Thorn in Cancer's Side?International journal of molecular sciences · 2025Article
- Arsenic sulfide enhances the therapeutic effect of hepatocellular carcinoma immunotherapy through STAT3-THBS1/CD47 pathway.Frontiers in immunology · 2025Article
- Elemene Injection Suppresses Pancreatic Cancer Progress through Regulating Cell Adhesion: A Research Based upon Network Pharmacology and Verification Test.Current medicinal chemistry · 2025Article
- PKCActa pharmaceutica Sinica. B · 2024Article
- Cocrystal@protein-anchoring nanococktail for combinatorially treating multidrug-resistant cancer.Acta pharmaceutica Sinica. B · 2024Article
- Circular RNA-encoded oncogenic PIAS1 variant blocks immunogenic ferroptosis by modulating the balance between SUMOylation and phosphorylation of STAT1.Molecular cancer · 2024Article
- Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective.EBioMedicine · 2024Review
- The CD47/TSP-1 axis: a promising avenue for ovarian cancer treatment and biomarker research.Molecular cancer · 2024Article
- Current advance of nanotechnology in diagnosis and treatment for malignant tumors.Signal transduction and targeted therapy · 2024Review
- Multifunctional nanoparticle-mediated combining therapy for human diseases.Signal transduction and targeted therapy · 2024Review
- Current research trends of nanomedicines.Acta pharmaceutica Sinica. B · 2023Review
- Pulmonary endothelium-targeted nanoassembly of indomethacin and superoxide dismutase relieves lung inflammation.Acta pharmaceutica Sinica. B · 2023Article
- Lipid carriers for mRNA delivery.Acta pharmaceutica Sinica. B · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The use of checkpoint-blockade antibodies is still restricted in several malignancies due to the modest efficacy, despite considerable success in anti-tumor immunotherapy. The poor response of cancer cells to immune destruction is an essential contributor to the failure of checkpoint therapy. We hypothesized that combining checkpoint therapy with natural-product chemosensitizer could enhance immune response. Herein, a targeted diterpenoid derivative was integrated with the checkpoint blockade (anti-CTLA-4) to improve immunotherapy using thermosensitive liposomes as carriers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.